| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2269 | Gls1 Inhibitor Ll202 | Novel inhibitor of glutaminase 1 (GLS1) with high binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM), exhibiting a similar in vivo antitumor activity as CB839 |
|
| DCC2270 | Glut4-activator-26b | Novel potent glucose transporter type 4 (GLUT4) translocation activator, showing a significant blood glucose lowering effect in the severe diabetic mice model |
|
| DCC2271 | Glut-i1 | Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
| DCC2272 | Glut-i2 | Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
| DCC2273 | Glut-i2-nh2 | Glucose transporter inhibitor linker for insulin conjugate |
|
| DCC2274 | Glut-in-30 | Novel glucose transporter (GLUT) inhibitor, exhibited high antitumor potency through the suppression of glucose uptake (IC 50 : 2.5 μM), while not cytotoxic to prostate and mammary epithelial cells |
|
| DCC2275 | Glycitin 6"-o-malonate | Metabolite of soy isoflavones, promoting the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover |
|
| DCC2276 | Gm3 N-12 | Novel GM3 derivative, showing excellent migration and invasion inhibitory effects in cells and marked antitumor activity in C57BL/6 mice, involving focal adhesion and ECM-receptor interaction signaling pathways |
|
| DCC2277 | Gma-839 | Selective modulator of gamma-aminobutyric acid(A) receptors |
|
| DCC2278 | Gmb-805 | Novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity |
|
| DCC2279 | Gmb-905 | Negative control for GMB-805 |
|
| DCC2280 | Gn39482 | Novel Tubulin Polymerization Inhibitor |
|
| DCC2281 | Gne-0723 | Novel GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of The N-methyl-d-aspartate receptor (NMDAR) |
|
| DCC2282 | Gne-0946 | Novel potent and selective RORc inverse agonist |
|
| DCC2283 | Gne-203 | Novel Met inhibitor |
|
| DCC2284 | Gne-3476 | Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM) |
|
| DCC2285 | Gne-5729 | Novel NMDAR PAM with both an improved pharmacokinetic profile and increased selectivity against AMPARs |
|
| DCC2286 | Gne-618 | Novel inhibitor of nicotinamide phosphoribosyl transferase (NAMPT) |
|
| DCC2287 | Gne-6689 | Negative control for GNE-2256 |
|
| DCC2288 | Gne-6901 | Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM) |
|
| DCC2289 | Gne-783 | Novel selective CHK1 inhibitor |
|
| DCC2290 | Gnf351 | Novel potent aryl hydrocarbon receptor (AHR) antagonist with the capacity to inhibit both DRE-dependent and -independent activity |
|
| DCC2292 | Gnf-pf-3539 | Novel Inhibitor of EGF-EGFR Interactions |
|
| DCC2293 | Gnf-pf-3600 | Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites |
|
| DCC2294 | gnf-pf-3834 | Dose dependent up-regulator of the level of E-cadherin in SW620 cells |
|
| DCC2295 | Gnidimacrin | Natural highly potent HIV latency-reversing agent |
|
| DCC2296 | Gnlpt-in-1 | Novel inhibitor of Gram-negative lipoprotein trafficking |
|
| DCC2297 | Gnmt Inducer K-117 | Novel potent GNMT inducer, inhibiting Huh7 cell growth in vitro and xenograft in vivo |
|
| DCC2298 | Go/ldha-in-7 | Dual Glycolate Oxidase/Lactate Dehydrogenase A (GO/LDHA) Inhibitor for Primary Hyperoxaluria |
|
| DCC2299 | Gonadorelin Acetate | Agonist of the GnRH receptor, inducing the secretion of the gonadotropins follicle-stimulating hormone and luteinizing hormone from the pituitary gland and to increase sex hormone production by the gonads |
|
